Skip to main
NTRA
NTRA logo

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 25 analyst ratings
Buy
Strong Buy 36%
Buy 60%
Hold 4%
Sell 0%
Strong Sell 0%

Bulls say

Natera Inc has demonstrated significant growth potential, with a projected 60% increase in clinical volume for its Signatera test in 2024, fueled by expanding payor coverage and higher recognized average selling prices (ASPs). The company's gross margins have improved markedly from the low 40s to approximately 60%, driven by a favorable product mix and recent enhancements in reimbursement rates, particularly for oncology tests. Additionally, Natera's robust performance during challenging market conditions, with revenues nearly sextupling since 2019, solidifies its position as a leader in the non-invasive prenatal testing and molecular residual disease markets, creating a solid foundation for future expansion in the $30 billion cancer screening total addressable market.

Bears say

Natera's recent quarterly performance fell short of expectations, primarily due to disruptions from electronic medical record (EMR) integration and seasonal holiday effects, which raises concerns about continued revenue growth. The company's 2025 revenue guidance is approximately $28.3 million below consensus, indicating potential challenges in achieving profitability, especially if payors reduce or eliminate reimbursement for its diagnostic services. Additionally, anticipated margin erosion from pricing pressures and the low enterprise value-to-sales ratio further underlines the financial risks facing Natera's future performance.

Natera (NTRA) has been analyzed by 25 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 60% recommend Buy, 4% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 25 analysts, Natera (NTRA) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $151.04, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $151.04, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.